Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451

• Status: Recruiting
• Trial end date: 2022-02-02
• Target enrollment: 0
• Participant gender: All

Summary

• the change of sitSBP based on baseline between Treatment arm and control 1 arm [ Time Frame: 8 weeks ]

• the change of LDL-C based on baseline between Treatment arm and control2 arm [ Time Frame: 8 weeks ]

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daewoong Pharmaceutical Co. LTD.
• Treatments: Amlodipine; Amlodipine Besylate, Olmesartan Medoxomil Drug Combination; Ezetimibe; Olmesartan; Olmesartan Medoxomil; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Age 19 to 80 years

• patients with hypertension and hyperlipidemias

Exclusion Criteria:

• orthostatic hypotension

• History of ventricular tachycardia, atrial fibrillation

• uncontrolled diabetes mellitus